We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Affymetrix and Iconix to Develop Solutions for Assessing Drug Toxicity

News   Feb 08, 2006

 
Affymetrix and Iconix to Develop Solutions for Assessing Drug Toxicity
 
 
Advertisement
 

RELATED ARTICLES

Two New Rapid COVID-19 Tests To Be Rolled Out in the UK Ahead of Winter

News

Millions of new rapid coronavirus tests will be rolled out across NHS hospitals, care homes and labs from next week. Both tests will be able to detect COVID-19 and other winter viruses in just 90 minutes and will hugely increase testing capacity ahead of winter.

READ MORE

Expert Panel Makes Weak Recommendation for Use of Remdesivir To Treat Severe COVID-19

News

International experts have made a weak recommendation for the use of remdesivir in patients with severe COVID-19, advising continuation of patient enrolment for ongoing clinical trials of remdesivir to enable the collection of additional data.

READ MORE

Pan-Bcl-2 and Bcl-xL-Specific Inhibitors: Adverse Effects From Cancer Drug Trials Explained

News

A certain type of cancer drug, known as pan-Bcl-2 or Bcl-xL-specific inhibitors, that promote the apotosis can actually be harmful if combined with other treatments that damage our DNA, RNA or proteins, researchers have found.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE